Total Payments
$12,401
2024 Payments
$2,075
Companies
80
Transactions
655
Medicare Patients
8,320
Medicare Billing
$3.5M
Payment Breakdown by Category
Food & Beverage$11,849 (95.5%)
Education$552.22 (4.5%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,849 | 636 | 95.5% |
| Education | $552.22 | 19 | 4.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $1,242 | 63 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $920.17 | 61 | $0 (2024) |
| PFIZER INC. | $856.86 | 66 | $0 (2024) |
| Janssen Biotech, Inc. | $831.18 | 41 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $524.43 | 24 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $432.88 | 17 | $0 (2023) |
| Merck Sharp & Dohme LLC | $410.83 | 24 | $0 (2024) |
| ABBVIE INC. | $409.90 | 19 | $0 (2024) |
| Genentech USA, Inc. | $375.01 | 21 | $0 (2024) |
| GENZYME CORPORATION | $354.18 | 17 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,075 | 95 | ABBVIE INC. ($254.67) |
| 2023 | $1,808 | 88 | AstraZeneca Pharmaceuticals LP ($317.10) |
| 2022 | $1,894 | 88 | Karyopharm Therapeutics Inc. ($216.36) |
| 2021 | $969.37 | 40 | Servier Pharmaceuticals LLC ($159.26) |
| 2020 | $708.64 | 39 | AstraZeneca Pharmaceuticals LP ($83.22) |
| 2019 | $2,228 | 128 | E.R. Squibb & Sons, L.L.C. ($249.31) |
| 2018 | $1,774 | 111 | PFIZER INC. ($235.16) |
| 2017 | $944.22 | 66 | E.R. Squibb & Sons, L.L.C. ($288.57) |
All Payment Transactions
655 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $41.10 | General |
| Category: Oncology | ||||||
| 12/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.62 | General |
| 12/11/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $32.29 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $21.52 | General |
| 12/05/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $11.73 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: Hematology | ||||||
| 12/03/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $30.38 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: ONCOLOGY | ||||||
| 11/25/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/22/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $20.06 | General |
| 11/15/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | ARRAY BIOPHARMA INC | XALKORI (Drug), LORBRENA, BRAFTOVI | Food and Beverage | In-kind items and services | $30.18 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $29.92 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $23.54 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 11/01/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $23.65 | General |
| Category: Oncology | ||||||
| 10/23/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Education | In-kind items and services | $59.95 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $29.92 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $26.87 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: ONCOLOGY | ||||||
| 10/11/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2024 | Genmab U.S., Inc. | Tivdak (Drug) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 30 | 2,173 | 126,991 | $6.2M | $1.5M |
| 2022 | 28 | 2,035 | 148,365 | $4.5M | $1.1M |
| 2021 | 39 | 2,309 | 129,190 | $3.1M | $571,981 |
| 2020 | 32 | 1,803 | 87,260 | $1.6M | $337,968 |
Total Patients
8,320
Total Services
491,806
Medicare Billing
$3.5M
Procedure Codes
130
All Medicare Procedures & Services
130 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 15 | 19,600 | $2.9M | $847,196 | 29.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 18 | 7,860 | $551,280 | $145,321 | 26.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 420 | 1,372 | $307,328 | $137,059 | 44.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 27 | 38,820 | $815,220 | $91,703 | 11.2% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 38 | 5,400 | $403,800 | $89,678 | 22.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 52 | 433 | $297,038 | $48,065 | 16.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 144 | 319 | $96,019 | $45,724 | 47.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 104 | 104 | $44,928 | $17,938 | 39.9% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 376 | 1,532 | $45,960 | $11,599 | 25.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 81 | 420 | $63,840 | $10,240 | 16.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 20 | 160 | $32,800 | $9,863 | 30.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 351 | 1,134 | $21,546 | $9,484 | 44.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 20 | 145 | $48,430 | $8,021 | 16.6% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 19 | 19,890 | $119,340 | $7,811 | 6.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 63 | 108 | $32,832 | $5,790 | 17.6% |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 2023 | 12 | 21,600 | $43,200 | $5,551 | 12.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 59 | 282 | $26,226 | $3,217 | 12.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 24 | 191 | $20,055 | $2,526 | 12.6% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 60 | $8,460 | $1,633 | 19.3% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 18 | 18 | $3,294 | $1,365 | 41.4% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 23 | 1,520 | $185,440 | $1,274 | 0.7% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 22 | 85 | $6,205 | $931.85 | 15.0% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2023 | 14 | 420 | $126,000 | $835.08 | 0.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 19 | 19 | $1,064 | $608.95 | 57.2% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 11 | 18 | $4,482 | $503.82 | 11.2% |
About Dr. Robert Roush, M.D
Dr. Robert Roush, M.D is a Hematology & Oncology healthcare provider based in Broomall, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508801085.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Roush, M.D has received a total of $12,401 in payments from pharmaceutical and medical device companies, with $2,075 received in 2024. These payments were reported across 655 transactions from 80 companies. The most common payment nature is "Food and Beverage" ($11,849).
As a Medicare-enrolled provider, Roush has provided services to 8,320 Medicare beneficiaries, totaling 491,806 services with total Medicare billing of $3.5M. Data is available for 4 years (2020–2023), covering 130 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Broomall, PA
- Active Since 06/18/2006
- Last Updated 02/06/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1508801085
Products in Payments
- IMBRUVICA (Drug) $658.02
- OPDIVO (Biological) $655.36
- KEYTRUDA (Biological) $384.03
- XPOVIO (Drug) $328.51
- LYNPARZA (Drug) $323.35
- IBRANCE (Drug) $279.83
- CALQUENCE (Drug) $260.09
- PADCEV (Biological) $244.28
- ERLEADA (Drug) $214.85
- JEVTANA (Drug) $208.47
- ELIQUIS (Drug) $185.49
- XTANDI (Drug) $176.75
- JAKAFI (Drug) $175.52
- DARZALEX (Biological) $165.87
- TAGRISSO (Drug) $165.04
- TIBSOVO (Drug) $159.26
- VERZENIO (Drug) $158.99
- ALIYA SYSTEM (Device) $152.02
- ADCETRIS (Biological) $149.41
- Nerlynx (Drug) $146.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.